Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aastrom Biosciences Receives NIH Grant for Dendritic Cell Vaccine Research
-- Study Expands Aastrom's Tumor Antigen Primed Vaccine Approach to Ovarian Cancer --
View HTML
Toggle Summary Aastrom Biosciences Receives FDA Approval to Initiate Multi-Center Clinical Trial for Bone Graft Product
-- IND Approval Key Milestone for Aastrom's Stem Cell Product Program for Tissue Generation --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter Financial Results
Aastrom Biosciences, Inc. Reports Fourth Quarter Financial Results Ann Arbor, Michigan, August 26, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today financial results for the fourth quarter and fiscal year ended June 30, 2003. The Company also reported significant achievements
View HTML
Toggle Summary Aastrom Biosciences Completes CE Mark Requirements for Third Dendritic Cell Therapy Product
-- Expands Aastrom's Cell Production Products Business --
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.